Integral Diagnostics Ltd (ASX: IDX) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Integral Diagnostics Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Integral Diagnostics Ltd (ASX: IDX)
Latest News
Healthcare Shares
How AI could boost this ASX 300 healthcare stock
Healthcare Shares
2 ASX healthcare shares with 'compelling' valuations to buy
Cheap Shares
'Compelling growth prospects': 2 ASX shares to buy while they're cheap
Share Fallers
Why Aussie Broadband, Bowen Coal, Integral Diagnostics, and Treasury Wine are falling today
Healthcare Shares
Guess which ASX All Ords share is crashing 30% today
Share Fallers
Why Atlantic Lithium, Integral Diagnostics, Nexted, and Serko shares are falling today
Healthcare Shares
Goldman Sachs has just slapped buy ratings on these ASX healthcare shares
Healthcare Shares
'Highly sought-after': 3 ASX healthcare shares ready to roar again
Share Fallers
Why Baby Bunting, Integral Diagnostics, Pilbara Minerals, and Zip shares are falling
Cheap Shares
3 ASX shares now at a golden buying opportunity: experts
Healthcare Shares
Goldman names 2 ASX healthcare shares to buy
Healthcare Shares
Goldman Sachs names 3 ASX healthcare shares to buy
Frequently Asked Questions
-
Yes, Integral Diagnostics historically pays two fully franked dividends a year.
-
Integral Diagnostics generally pays its shareholder dividends in April and October.
-
Integral Diagnostics Ltd listed on the ASX on 21 October 2015.
Dividend Payment History Data provided by Morningstar.
Ex-Date | Amount | Franking | Type | Payable |
---|---|---|---|---|
29 Feb 2024 | $0.0250 | 100.00% | Interim | 02 Apr 2024 |
31 Aug 2023 | $0.0350 | 100.00% | Final | 04 Oct 2023 |
02 Mar 2023 | $0.0250 | 100.00% | Interim | 04 Apr 2023 |
01 Sep 2022 | $0.0300 | 100.00% | Final | 05 Oct 2022 |
01 Mar 2022 | $0.0400 | 100.00% | Interim | 04 Apr 2022 |
02 Sep 2021 | $0.0700 | 100.00% | Final | 06 Oct 2021 |
01 Mar 2021 | $0.0550 | 100.00% | Interim | 06 Apr 2021 |
28 Aug 2020 | $0.0400 | 100.00% | Final | 01 Oct 2020 |
28 Feb 2020 | $0.0550 | 100.00% | Interim | 07 Apr 2020 |
30 Aug 2019 | $0.0500 | 100.00% | Final | 02 Oct 2019 |
01 Mar 2019 | $0.0500 | 100.00% | Interim | 02 Apr 2019 |
31 Aug 2018 | $0.0400 | 100.00% | Final | 04 Oct 2018 |
31 Jan 2018 | $0.0400 | 100.00% | Interim | 05 Mar 2018 |
31 Aug 2017 | $0.0000 | 100.00% | Final | 04 Oct 2017 |
28 Feb 2017 | $0.0300 | 100.00% | Interim | 30 Mar 2017 |
31 Aug 2016 | $0.0400 | 100.00% | Final | 04 Oct 2016 |
IDX ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About Integral Diagnostics Ltd
Integral Diagnostics Ltd (ASX: IDX) is an Australian healthcare services company providing medical imaging services.
The group operates in a single business providing diagnostic imaging to general practitioners, medical specialists, and allied health professionals and their patients.
The company operates more than 90 radiology clinics across Australia and New Zealand. It is also a joint venture partner in Medx, expanding its services to the United Kingdom and Ireland.
IDX Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
24 Apr 2024 | $2.51 | $-0.05 | -1.95% | 890,177 | $2.59 | $2.59 | $2.49 |
23 Apr 2024 | $2.56 | $0.02 | 0.79% | 353,013 | $2.56 | $2.59 | $2.53 |
22 Apr 2024 | $2.54 | $0.07 | 2.83% | 842,603 | $2.47 | $2.58 | $2.47 |
19 Apr 2024 | $2.47 | $-0.01 | -0.40% | 317,049 | $2.49 | $2.49 | $2.45 |
18 Apr 2024 | $2.48 | $0.03 | 1.22% | 477,965 | $2.47 | $2.49 | $2.44 |
17 Apr 2024 | $2.45 | $0.03 | 1.24% | 544,580 | $2.45 | $2.47 | $2.41 |
16 Apr 2024 | $2.42 | $0.05 | 2.11% | 557,284 | $2.41 | $2.43 | $2.35 |
15 Apr 2024 | $2.37 | $0.00 | 0.00% | 319,773 | $2.38 | $2.38 | $2.35 |
12 Apr 2024 | $2.37 | $0.01 | 0.42% | 279,727 | $2.36 | $2.38 | $2.33 |
11 Apr 2024 | $2.36 | $-0.02 | -0.84% | 175,083 | $2.35 | $2.39 | $2.34 |
10 Apr 2024 | $2.38 | $-0.01 | -0.42% | 587,508 | $2.40 | $2.40 | $2.35 |
09 Apr 2024 | $2.39 | $-0.01 | -0.42% | 296,650 | $2.40 | $2.43 | $2.38 |
08 Apr 2024 | $2.40 | $0.02 | 0.84% | 394,144 | $2.41 | $2.42 | $2.37 |
05 Apr 2024 | $2.38 | $0.02 | 0.85% | 458,483 | $2.35 | $2.39 | $2.32 |
04 Apr 2024 | $2.36 | $-0.07 | -2.88% | 500,053 | $2.43 | $2.43 | $2.33 |
03 Apr 2024 | $2.43 | $0.16 | 7.05% | 1,275,061 | $2.26 | $2.43 | $2.25 |
02 Apr 2024 | $2.27 | $0.02 | 0.89% | 779,869 | $2.28 | $2.30 | $2.23 |
28 Mar 2024 | $2.25 | $0.03 | 1.35% | 222,587 | $2.23 | $2.26 | $2.22 |
27 Mar 2024 | $2.22 | $-0.04 | -1.77% | 384,949 | $2.25 | $2.26 | $2.21 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
02 Apr 2024 | James Hall | Issued | 1,719 | $3,748 |
Dividend Reinvestment Plan (DRP). As per announcement on 04-04-2024
|
02 Apr 2024 | James Hall | Issued | 1,719 | $3,748 |
Dividend Reinvestment Plan (DRP).
|
01 Dec 2023 | Andrew Fay | Buy | 15,000 | $25,575 |
On-market trade.
|
01 Dec 2023 | Ian Kadish | Buy | 20,000 | $35,050 |
On-market trade.
|
30 Nov 2023 | Ian Kadish | Issued | 248,970 | $441,921 |
Issue of securities. 858,583 - Rights
|
30 Nov 2023 | Ingrid Player | Buy | 35,000 | $60,725 |
On-market trade.
|
30 Nov 2023 | James Hall | Buy | 150,000 | $258,225 |
On-market trade.
|
20 Sep 2023 | Ian Kadish | Issued | 26,035 | $75,241 |
Issue of securities. 6,09,613 Performance Rights
|
28 Aug 2023 | Ian Kadish | Expiry | 435,572 | $1,354,628 |
As advised by the company. Lapse of rights, 583,578 Rights
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Mr Andrew James Fay | Non-Executive Director | Jul 2022 |
Mr Fay brings to the Board over 30 years of experience in funds and investment management, including Chief Executive Officer and Chief Investment Officer roles at Deutsche Asset Management (Australia) Limited. He also held several other senior investment roles at Deutsche Asset Management and previously at AMP Capital. From 1998 to 2006, he was a member of the Investment Board Committee of the Financial Services Council. Andrew is an experienced company director across ASX listed, private and regulated entities and accordingly brings to the Board skills in financial and risk management, capital markets, executive remuneration frameworks, strategy, investment, and corporate governance. Specifically, he has sector experience and expertise in financial services, including investment, funds, property and infrastructure management. He is also Member of the Risk and Compliance Committee.
|
Dr Jacqueline Milne | Executive Director | Nov 2019 |
Dr Milne Dr Milne is a full-time permanently employed radiologist of the Company based in Queensland and is therefore considered by the Board to be a Non-Independent Executive Director. While Dr Milne is not an independent director by virtue of her employment, she is independent of senior management and her responsibilities do not extend to the day-to-day management of the Company. She is Member of the Integral Clinical Leadership Committee.
|
Ms Raelene Margaret Murphy | Non-Executive Director | Oct 2017 |
Ms Murphy has over 30 years of experience in strategic, financial, and operational leadership in both industry and professional advisory, after beginning her career in audit. She was formerly a Partner in a national accounting firm, Managing Director of Korda Mentha and CEO of the Delta Group. In her professional advisory career, she specialized in operational and financial restructuring, with a particular emphasis on merger and acquisition integration across a range of public and private companies. Raelene is a Fellow of Chartered Accountants Australia and New Zealand and has extensive experience as Chair of Audit and Risk Committees for ASX listed companies. She is Chair of the Risk and Compliance Committee.
|
Ms Ingrid Anne Player | Non-Executive Director | Aug 2023 |
Ms Player has more than 20 years experience in the healthcare industry, gained from leadership roles across the private, public and not for profit sectors. In her executive career, Ms Player was Group Executive Legal, Governance and Sustainability at Healthscope, one of Australias largest private healthcare providers. As a qualified lawyer, she previously worked in private legal practice in Australia and Europe specialising in corporate law, M&A and capital markets. She brings to the Board experience in leveraging corporate transactions and major capital projects to achieve strategic outcomes, as well as skills in risk management, government relations, sustainability and corporate governance. She currently serves as a Non-Executive Director of Cleanaway Management Ltd (ASX:CWY), Cogstate Ltd (ASX:CGS), Epworth Foundation and HealthShare Victoria
|
Mr James Tobias Hall | Non-Executive Director | Sep 2023 |
Mr Hall has experience in Australia and New Zealand and is an experienced Board and Committee Chair. Mr Hall was Group CEO of St Vincents Health Australia from 2014 to 2022, He has also overseen multisite, for-profit generating businesses at both board and executive levels in employment services, early learning services and aged care. His experience in M&A includes the acquisition of ABC Childcare from administration. Mr Hall is currently non-executive Chair of Sana Health Group, non-executive Chair of For Purpose Aged Care, non-executive Director of UNICEF Australia, a trustee of Yajilarra (a philanthropic foundation) and advisory board member for Fujitsu Australia and New Zealand. His former non-executive roles include Chair of ASX listed Sterihealth, board member of Goodstart Early Learning, board member of Working Links (a UK based for profit employment service) and two New Zealand based community built regional hospitals.
|
Dr Ian Kadish | Chief Executive OfficerManaging Director | May 2017 |
Mr Kadish began his career as a medical doctor in Johannesburg, South Africa. Ian was helpful in growing the group from five hospitals with a market capitalisation of $60m, to 119 hospitals and a market capitalisation of $3bn. Since migrating to Australia in 2006, Dr Kadish's roles have included CEO and MD of Healthcare Australia, CEO and MD of Pulse Health Group and CEO of Laverty Pathology. He is also a Director of the Australian Diagnostic Imaging Association (ADIA). He is also Member of the Integral Clinical Leadership Committee.
|
Ms Nikki Dalla Valle | Company Secretary | Dec 2023 |
-
|
Craig White | Chief Financial Officer |
-
|
|
Paul McCrow | Chief Operating Officer |
-
|
|
Nikki Dalla Valle | Company Secretary |
-
|
|
Jacqueline Milne | Radiologist Executive Director |
-
|
|
Nazar Bokani | Radiologist Executive Director |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
HSBC Custody Nominees (Australia) Limited | 41,305,475 | 17.73% |
Citicorp Nominees Pty Limited | 37,720,613 | 16.19% |
J P Morgan Nominees Australia Pty Limited | 30,949,506 | 13.28% |
National Nominees Limited | 12,416,583 | 5.33% |
BNP Paribas Nominees Pty Ltd Hub24 Custodial Serv Ltd <DRP A/C> | 4,309,344 | 1.85% |
BNP Paribas Noms Pty Ltd <DRP> | 3,943,475 | 1.69% |
Hsbc Custody Nominees (Australia) Limited <Nt Comnwlth Super Corp A/C> | 3,469,048 | 1.49% |
New Imaging Pty Ltd <New Imaging A/C> | 3,389,045 | 1.45% |
Washington H Soul Pattinson And Company Limited | 3,290,936 | 1.41% |
Citicorp Nominees Pty Limited <Colonial First State INV A/C> | 3,276,722 | 1.41% |
Lethean Holdings Pty Ltd <Howitt No 8 A/C> | 2,944,760 | 1.26% |
J A Mullins Pty Ltd <James A Mullins Family A/C> | 2,616,051 | 1.12% |
Firbar Pty Ltd <The Howitt No 4 A/C> | 2,357,230 | 1.01% |
Lockwood Ridge Pty Ltd <The AJ French Family A/C> | 2,177,058 | 0.93% |
Mittal Holdings Pty Ltd <Howitt No 12 A/C> | 2,085,907 | 0.90% |
Mr Vincent Michael O'sullivan <O'sullivan A/C> | 2,059,000 | 0.88% |
Wyndham Salter Pty Ltd <The Howitt No 10 A/C> | 1,862,947 | 0.80% |
Masfen Securities Limited | 1,710,000 | 0.73% |
Netwealth Investments Limited <Wrap Services A/C> | 1,605,935 | 0.69% |
BNP Paribas Noms (NZ) Ltd <DRP> | 1,509,566 | 0.65% |